Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brepocitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 known ✓ | P23458 | 20/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 16/20 | 1.00 |
| ▸ | JAK2 | O60674 | 16/20 | 1.00 |
| ▸ | JAK3 | P52333 | 5/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | STAT1 | P42224 | 1/20 | 1.00 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brepocitinib SCHEMBL24173034 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL17512502 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL31291113 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL24172497 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL17512520 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL24293069 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL24172557 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL27018910 | 0.94 | JAK1 (0.90) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL20767478 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL25180897 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282789-A1 | CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4181874-B1 | STABLE PHARMACEUTICAL TOPICAL FORMULATION CONTAINING IMMUNOSUPPRESSANT | PFIZER (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20230277537-A1 | STABLE PHARMACEUTICAL TOPICAL FORMULATION CONTAINING IMMUNOSUPPRESSANT FOR TREATING DERMATOLOGICAL CONDITION | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230277537-A1 | STABLE PHARMACEUTICAL TOPICAL FORMULATION CONTAINING IMMUNOSUPPRESSANT FOR TREATING DERMATOLOGICAL CONDITION | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230277537-A1 | STABLE PHARMACEUTICAL TOPICAL FORMULATION CONTAINING IMMUNOSUPPRESSANT FOR TREATING DERMATOLOGICAL CONDITION | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20220339151-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | CELGENE CORPORATION | 2022-10-27 | — | — | US | disclosed |
| US-11357775-B2 | Combination therapies comprising apremilast and Tyk2 inhibitors | CELGENE CORPORATION (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022013708-A1 | STABLE PHARMACEUTICAL TOPICAL FORMULATION CONTAINING IMMUNOSUPPRESSANT FOR TREATING DERMATOLOGICAL CONDITIONS | PFIZER INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| EP-3924355-A1 | CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF | Pfizer Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20200345731-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | CELGENE CORPORATION | 2020-11-05 | — | — | US | disclosed |
| WO-2020222773-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | CELGENE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223431-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | CELGENE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020165788-A1 | CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345731-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | PDE4A, TYK2, PDE4B | JAK1 23/4885TYK2 2/4885JAK2 113/4885 |
| US-20250282789-A1 | CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF | PDXK, OR10J3, CYP2J2 | JAK1 1391/4885TYK2 531/4885JAK2 2925/4885 |
| US-11357775-B2 | Combination therapies comprising apremilast and Tyk2 inhibitors | PDE4A, TYK2, PDE4B | JAK1 23/4885TYK2 2/4885JAK2 113/4885 |
| US-20220339151-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | PDE4A, TYK2, PDE4B | JAK1 23/4885TYK2 2/4885JAK2 113/4885 |
| US-20230277537-A1 | STABLE PHARMACEUTICAL TOPICAL FORMULATION CONTAINING IMMUNOSUPPRESSANT FOR TREATING DERMATOLOGICAL CONDITION | JAK1, IL2, IL5 | JAK1 1/4885TYK2 79/4885JAK2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.